Shares in  Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY) , the consumer goods company behind Dettol and Nurofen, rose over 4% on Tuesday as investors digested a legal win for its Mead Johnson unit and a JP Morgan upgrade to overweight.

The upgrade came in a wider note on European consumer staples published by JP Morgan analyst Celine Pannuti on Tuesday.

On Monday, a US federal jury cleared Mead Johnson, Reckitt Benckiser's infant nutrition business, of liability in the first federal trial over claims that its Enfamil premature infant formula caused a fatal bowel disorder.

JPM also placed Heineken, the Dutch brewer, and Unilever, the consumer goods group, on positive "catalyst watch," ahead of upcoming results.

The bank said it remained cautious on household and hygiene companies, keeping Haleon and Essity at underweight, meaning it expects them to underperform.

It also stayed on the sidelines for beauty stocks, citing decelerating growth at L'Oréal, which it rates neutral.

European staples stocks are trading at 18 times forecast earnings for the next 12 months, a 23% premium to the wider market, below their long-term average premium of around 43%.

JPM's estimates for 2027 sit 1% to 2% below consensus, mainly reflecting weaker margins amid higher costs and net financial expenses.

In the beverages sector, the bank said recent profit-taking in beer stocks looked overdone and expects earnings to keep compounding at a high single-digit rate into 2027.

Carlsberg was identified as offering the best value and EPS growth in the sector, while JP Morgan kept a neutral rating on Campari but flagged a near-term preference ahead of an expected third-quarter like-for-like sales beat and margin upside.